37 search results for: asthma

Airway Hyperresponsiveness In <b>Asthma</b> Is Mainly Driven By Components Of Type 2 Inflammation
Pulmonology
Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation
interactivity

Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.

View more
The Burden in Patients with CRSwNP and Coexisting <b>Asthma</b>
Pulmonology
The Burden in Patients with CRSwNP and Coexisting Asthma
expert video

This video supports improved clinical awareness and encourages comprehensive care strategies for patients living with both CRSwNP and asthma.

View more
Screen depicting a mucus plug in the airways
Pulmonology
A view into the Airway: The Pathophysiology and Clinical Relevance of Mucus Plugs in Asthma
videoanimation

Explore the role of type 2 inflammation in the production of mucus plugs in asthma and the effects these plugs can have on patients.

View more
ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With <b>Asthma</b>
Pulmonology
ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma
Podcast

Join Professors Klaus Rabe and Ian Pavord as they discuss the importance of on-treatment clinical remission as a goal in asthma management.

View more
Corticosteroids in <b>Asthma</b> Management
Pulmonology
Corticosteroids in Asthma Management
Infographic

This infographic illustrates the ongoing burden associated with maintenance oral corticosteroid (OCS) use and high-dose inhaled corticosteroids (ICS) in asthma, including the clinical impact of corticosteroid exposure, supporting evidence, and the importance of considering corticosteroid burden in asthma management.

View more
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 <b>Asthma</b>
Pulmonology
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma
expert video

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.

View more
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for <b>Asthma</b> Patients
Pulmonology
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients
Infographic

Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.

View more
ERS 2026 | Distal Airways, Central Role? Clinical Insights Into Type 2 Severe <b>Asthma</b>
Pulmonology
ERS 2026 | Distal Airways, Central Role? Clinical Insights Into Type 2 Severe Asthma
expert video

Join experts Frederik Trinkmann, Monica Kraft, and Arnaud Bourdin on an ADVENT educational symposium, “Distal Airways, Central Role? Clinical Insights Into Type 2 Severe Asthma."

View more
Spotlight on Type 2 Inflammation in the Upper and Lower Airways
Pulmonology
Spotlight on Type 2 Inflammation in the Upper and Lower Airways
expert video

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.

View more
Compounded Burden of Co-existing Type 2 Airway Diseases
Pulmonology
Compounded Burden of Co-existing Type 2 Airway Diseases
expert video

In this video soundbite from the EAACI 2025 symposium, Dr. Brian Lipworth discusses that co-existing type 2 inflammatory diseases are common in patients with CRSwNP​ & increasing severity of asthma is associated with higher severity of CRS and prevalence of nasal polyps. Additionally, he explains that patient burden is substantially greater when asthma and CRSwNP are co-existing.

View more
EAACI 2024 | On-Treatment Clinical Remission in Upper and Lower Airways: ​ Going Beyond Symptom Control​
Congress
31
May
2024
Congress
EAACI 2024 | On-Treatment Clinical Remission in Upper and Lower Airways: ​ Going Beyond Symptom Control​

Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.

thumbnail
Congress
19
October
2026
Congress
ADVENT at CHEST 2026

At CHEST 2026, the Sanofi & Regeneron ADVENT Booth #833 brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.​